Robinhood stock slides after-hours as order-flow settlement notice hits wires, traders eye earnings
7 January 2026
1 min read

Robinhood stock slides after-hours as order-flow settlement notice hits wires, traders eye earnings

New York, Jan 6, 2026, 18:00 ET — After-hours

  • Shares down 1.2% after hours, extending a choppy start to 2026
  • Settlement administrator published details of a proposed $2 million order-flow case resolution
  • Next big marker: Feb. 10 results, with U.S. labor data due Wednesday

Robinhood Markets shares slipped 1.2% in after-hours trading on Tuesday after a settlement administrator published details of a proposed $2 million resolution in long-running “order flow” litigation. The stock was last at $121.70. 1

The notice matters because it reopens scrutiny of how trades get routed and priced — a sensitive issue for retail brokerages. The case focuses on market orders executed at worse prices than the “national best bid or offer,” the top quoted prices in public markets.

The legal update landed as investors continue to trade Robinhood as a proxy for risk appetite in digital assets and high-turnover retail trading. On Tuesday, Morgan Stanley filed for bitcoin and solana exchange-traded funds, another sign traditional finance is pushing deeper into crypto products. 2

Robinhood has been trying to hold on to heavier traders by sharpening its crypto tools, according to a report that cited Johann Kerbrat, head of crypto at Robinhood. Kerbrat said some newer customers see dips as “‘buy the dip’ opportunities,” while more sophisticated users trade more actively. 3

Investors also have an earnings checkpoint coming up. Robinhood said it will report fourth-quarter and full-year 2025 results on Feb. 10, after the close, with Chief Executive Vlad Tenev and incoming Chief Financial Officer Shiv Verma scheduled to discuss results on a video call. 4

Technicians note the stock is hovering around key trend lines, trading above its 50-day moving average of about $117.75 but below the 200-day moving average near $123.06, according to Investing.com. The stock’s 52-week range runs from $29.66 to $153.86, Yahoo Finance data showed. 5

Still, the downside case is straightforward: legal and regulatory friction around order execution can raise costs or curb product flexibility, while swings in crypto prices can quickly cool trading volumes. Either can squeeze transaction-driven revenue and weigh on sentiment.

What investors watch next is Wednesday’s U.S. Job Openings and Labor Turnover Survey (JOLTS) report at 10:00 a.m. ET and a Federal Reserve speech later in the day — both potential inputs for rate expectations that can sway higher-beta growth stocks. 6

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Intel stock rises after hours as CES “Panther Lake” debut and Melius upgrade sharpen focus on 18A
Previous Story

Intel stock rises after hours as CES “Panther Lake” debut and Melius upgrade sharpen focus on 18A

MSCI hits pause on crypto index kick-out plan — Strategy pops after-hours
Next Story

MSCI hits pause on crypto index kick-out plan — Strategy pops after-hours

Go toTop